Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

NCT05501886 is registered in ClinicalTrials.gov with Celcuity Inc as lead sponsor.

NCT NCT05501886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05501886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
Lead sponsor
Celcuity Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 8, 2022
Completion date
December 31, 2026
Enrollment
701 (estimated)
Sites
235

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer